Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-06-26
2007-06-26
Angell, Jon E. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500
Reexamination Certificate
active
10327776
ABSTRACT:
The present invention provides novel antisense oligonucleotides that target the genes and mRNAs encoding mammalian Estrogen Receptors (ER) alpha and/or beta and modulate the receptors' responses. These antisense oligonucleotides may be used alone or in combination with 17 Beta estradiol or a related compound (genistein, estradiol derivatives . . . ) to improve plaque stabilization, vascular healing and endothelial recovery after vascular injury. Also provided are methods for designing and testing the antisense oligonucleotides. Such oligonucleotides may be used to modulate the beneficial effects mediated by the ER on vascular healing, for example, restenosis or plaque stabilisation, in mammals. The present invention further pertains to pharmaceutical compositions and formulations comprising the novel antisense oligonucleotides of the present invention for use in the treatment of mammals having a disease or disorder characterised by atherosclerosis, plaque vulnerability or destabilisation or pathological plaque rupture or erosion including spontaneous or induced injury.
REFERENCES:
patent: 5958710 (1999-09-01), Kuiper et al.
patent: WO 99/54459 (1999-10-01), None
patent: WO 01/69262 (2001-09-01), None
patent: WO 03/050133 (2003-06-01), None
Branch, A good antisense molecule is hard to find, TIBS, Feb. 1998, pp. 45-50.
Green et al., Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease, J Am Coll Surg, Jul. 2000, vol. 191, No. 1, pp. 93-105.
Jen et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells, 2000, 18:307-319.
Crooke, ST et al., Pharmacokinetic properties of several novel oligonucleotide analogs in mice. vol. 277, Issue 2, pp. 923-937, May 1, 1996, Copyright 1996 by American Society for Pharmacology and Experimental Therapeutics.
Johnston, Stephen A. et al., Functional Domains of the Yeast Regulatory Protein GAL4, Proceedings of the National Academy of Sciences of the United States of America, vol. 83, Issue 17 (Sep. 1, 1986), 6553-6557.
Manoharan, M et al., Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antinsense Applications, Bioorganic & Medicinal Chemistry Letters, vol. 3, No. 12, pp. 2765-2770, 1993.
Manoharan, M et al., Lipidic Nucleic Acids, Tetrahedron Letter, vol. 36, No. 21, pp. 3651-3654, 1995.
Manoharan, M et al., Cholic Acid-Oligonucleotide Conjugates for Antisense Applications, Bioorganic & MedicinalChemistry Letter, vol. 4, No. 8, pp. 1053-1060, 1994.
Mishra, R et al., Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-mediated delivery, Biochimica et Biophysica Acta 1264 (1995) 229-237, 1995.
Nielsen, P et al., Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide, Science; Dec. 6, 1991;254,5037; Research Library Core p. 1497.
Oberhauser, B and Wagner, E., Effective incorporation of 2′-O′methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol, Institute of Molecular Pathology, Vienna, Austria, abstract only.
Saison-Behmoaras, T et al., Short modified antisense oligonucleotides directed against Haras point mutation induce selective cleavage of the MRNA and inhbit T24 cells prliferation, The EMBO Journal, vol. 10, pp. 1111-1118, 1991. Copyright European Molecular Biology Organization, abstract only.
Shea, R et al., Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates, NucleicAcids Research, vol. 18, Issue 13, pp. 3888-3783, Copyright 1990 by Oxford University Press, abstract only.
Crooke, S et al., Antisense Research and Applications, ISBN: 084934705x, Publication Date: May 27, 1993, abstract only.
Manorharan, M et al., Chemical modifications to improve uptake and bioavailability of antisense oligonucleotides, Ann NY Acad Aci, 1992 660, pp. 306-309.
Cignarella A., Paoletti R., Puglisi L.; Direct Effects of Estrogen on the Vessel Wall; Med. Res. Rev.; 2001;21:171-84.
Song, J. Wan Y., Rolfe B.E., et al.; Effect of Estrogen on Vascular Smooth Muscle Cells is Dependent upon Cellular Phenotype; Atherosclerosis; 1998; 140:97-104.
Lavigne M.C., Ramwell P.W., Clarke R.; Inhibition of Estrogen Receptor Function Promotes Porcine Coronary Artery Smooth Muscle Cell Proliferation; Steriods; 1999; 64: 472-80.
Akishita M., Ouchi Y., Miyoshi H. et al.; Estrogen Inhibits Cuff-Induced Intimal Thickening of Rat Femoral Arterty; Effects of Migration and Proliferation of Vascular Smooth Muscle Cells; Atherosclerosis; 1997; 130:1-10.
Lantin-Hermoso R.L., Rosenfeld C.R., Yuhanna I.S., et al.; 15 Estrogen Acutely Stimulates Nitric Oxide Synthase Activity In Fetal Pulmonary Artery Endothelium; Am. J. Physiol.; 1997; 2731119-26.
Herrington D.; Role of Estrogens, Selective Estrogen Receptor Modulators and Phytoestrogens in Cardiovascular Protection; Can. J. Cardiol.; 2000; 16 Suppl. E:5E-9E.
Cenci S., Weitzmann M.N., Roggia C., et al.; Estrogen Deficiency Induces Bone Loss by Enhancing T-cell Production of TNF-alpha; J. Clin. Invest.; 2000-106:1229-37.
Silbiger S., Lei J., Ziyadeh, F.N., et al.; Estradiol Reverses TGF-beta1-stimulated Type IV Collagen Gene Transcription in Murine Mesangial Cells; Am. J. Physiol.; 1998; 274:FI 113-8.
Chandrasekar B., Tanguay, J.F.; Local Delivery of 17-beta-estradiol Decreases Neointimal Hyperlasia After Coronary Angioplasty in a Porcine Model; J. Am. Coll. Cardiol; 2000; 36:1972-8.
Mendelsohn, M.E., Karas, R.H.; The Protective Effects of Estrogen on the Cardiovascular System; N. Engl. J. Med.; 1999; 340: 180111.
Hayashi, K., Takahashi, M. Kirura, K., et al.; Changes in the Balance of Phosphoinositide 3-Kinase/protein Kinase B (Akt) and the Mitogen-Activated Protein Kinases (ERK/p38MAPK) determine a phenotype of visceral and Vascular Smooth Muscle Cells; J. Cell. Biol.; 1999; 145:727-40.
Simoncini, T., Genazzani, A.R.; Direct Vascular Effects of Estrogens and Selective Estrogen Receptor Modulators; Curr. Opin. Obstet. Gynecol.; 2000; 12; 12:181-7.
Finking G., Krauss N., Romer S., et al., 17-beta-estradiol, Gender Independently, Reduces Atheroma Development But Not 20 Neointimal Proliferation After Balloon Injury in the Rabbit Aorta; Atherosclerosis; 2001; 154:39-49.
Clarke S.C., Schofield P.M., Grace A.A., et al.; Tamoxifen Effects on Endothelial Function and Cardiovascular Risk Factors In Men With Advanced Atherosclerosis Circulation; 2001; 103:1497-502.
Van Baal W.M., Kenemans P., Emeis J.J., et al.; Longterm Effects of Combined Hormone Replacement Therapy on Markers of Endothelial Function and Inflammatory Activity in Healthy Postmenopausal Women; Fertil. Steril.; 1999; 71:663-70.
Sader M.A., McCredie R.J., Griffiths K.A., et al.; Oestradiol Improves Arterial Endothelial Function in Healthy Men Receiving Testosterone; Clin. Endocrinol (Oxf).; 2001; 54:175-81.
Shaul P.W.; Novel Role of Estrogen Receptors in Vascular Endothelium; Semin. Perinatol; 2000; 24:70-4.
Razandi M., Pedram A., Levin E.R.; Estrogen Signals to the Preservation of Endothelial Cell Form and Function; J. Biol. Chem.; 2000; 275:38540-6.
Giguere V., Tremblay A., Tremblay G.B.; Estrogen Receptor Beta: Re-evaluation of Estrogen and Antiestrogen Signaling; Steroids; 1998; 63:335-9.
Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Cariquist M.; Molecular Basis of Agonism and Antagonism in the Oestrogen Receptor; Nature; 1997; 389:753-8.
Evans M.J., Harris H.A., Miller C.P., Karathanasis S.K., Adelman S.J.; Estrogen Receptors Alpha and Beta Have Similar Activities in Multiple Endothelial Cell Pathways; Endocrinology; 2002; 143:3785-95.
Grodstein F., Manson J.E., Stampfer M.J.; Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study—A Prospective, Observational Study; Ann. Intern. Med.; 2001; 135:1-8.
Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D.; Postmenopausal Hormone Replacement The
Sirois Martin
Tanguay Jean-François
Angell Jon E.
Bowman Amy H.
Institut de Cardiologie de Montreal
Mathews, Shepherd, McKay & Bruneau, P.A.
LandOfFree
Antisense strategy to modulate estrogen receptor response... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense strategy to modulate estrogen receptor response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense strategy to modulate estrogen receptor response... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3828335